二甲双胍联合或不联合地中海饮食预防代谢综合征患者年龄相关疾病:MeMeMe随机试验
MeMeMe试验将1442名代谢综合征患者随机分配至二甲双胍1700 mg/日联合地中海饮食干预、安慰剂联合地中海饮食干预、单用二甲双胍1700 mg/日或单用安慰剂四组,平均随访3年。主要非传染性疾病粗发病率在二甲双胍联合地中海饮食组为6.7例/100人年,单用二甲双胍组为6.9,安慰剂联合地中海饮食组为13.3,安慰剂组为11.3,差异完全由2型糖尿病减少解释,二甲双胍组和二甲双胍联合地中海饮食组分别较安慰剂降低80%和92%。
要点
- 二甲双胍1700 mg/日可有效预防代谢综合征人群发生糖尿病。
- 主要非传染性疾病发病率的降低完全由2型糖尿病减少所解释。
- 二甲双胍联合地中海饮食组和单用二甲双胍组的2型糖尿病分别较安慰剂降低92%和80%。
核心结论
- 使用二甲双胍1700 mg/日可有效预防基于代谢综合征筛选的人群发生糖尿病。
研究设计与样本
- MeMeMe随机试验将1442名代谢综合征患者随机分配至二甲双胍1700 mg/日联合地中海饮食干预组、安慰剂联合地中海饮食干预组、单用二甲双胍1700 mg/日组或单用安慰剂组,平均随访3年。
主要发现
- 主要非传染性疾病粗发病率在二甲双胍联合地中海饮食组为6.7例/100人年,单用二甲双胍组为6.9例/100人年,安慰剂联合地中海饮食组为13.3例/100人年,安慰剂组为11.3例/100人年。
- 上述差异完全由2型糖尿病减少所解释,二甲双胍组和二甲双胍联合地中海饮食组的2型糖尿病分别较安慰剂降低80%和92%。
关键数值与推荐
- 主要结局为重大非传染性疾病(包括2型糖尿病、心血管疾病和癌症)的累积发病率。
- 次要结局为2型糖尿病发病率和代谢综合征患病率变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Metformin and Dietary Restriction to Prevent Age-Related Morbid Events in People With Metabolic Syndrome (MeMeMe) trial tested whether 1,700 mg/day metformin (MET) with or without a Mediterranean diet (MedDiet) intervention could reduce the cumulative incidence of major noncommunicable diseases in people with metabolic syndrome. RESEARCH DESIGN AND METHODS: A total of 1,442 participants were randomly assigned to one of four interventions: 1) MET (1,700 mg/day) plus MedDiet intervention (MET+MedDiet); 2) placebo plus MedDiet intervention; 3) MET (1,700 mg/day) alone; and 4) placebo alone. Participants were followed up for 3 years on average. The primary outcome was the cumulative incidence of major noncommunicable diseases (including type 2 diabetes, cardiovascular diseases, and cancer). Secondary outcomes were the incidence of type 2 diabetes and the changing prevalence of metabolic syndrome. RESULTS: The crude incidence of the major noncommunicable diseases was 6.7 cases per 100 person-years in the MET+MedDiet group, 6.9 in the MET alone group, 13.3 in the placebo plus MedDiet group, and 11.3 in the placebo group. The differences were fully explained by the reduction of type 2 diabetes, which was 80% and 92% lower in the MET and MET+MedDiet groups, respectively, compared with placebo. CONCLUSIONS: The use of 1,700 mg/day MET is effective to prevent diabetes in people selected on the basis of metabolic syndrome.
引用
- Pasanisi P, Oliverio A, Baldassari I, et al. Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial. Diabetes Care. 2025. PMID: 39641916. doi:10.2337/dc24-1597
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。